αvβ3 integrin antagonist S247 decreases colon cancer metastasis and angiogenesis and improves survival in mice

Cancer Research

Volumn 63, Issue 9, 2003, Pages 2079-2087

  Reinmuth, Niels ^a   Liu, Wenbiao ^a   Ahmad, Syed A ^a   Fan, Fan ^a   Stoeltzing, Oliver ^a   Parikh, Alexander A ^a   Bucana, Corazon D ^a   Gallick, Gary E ^a   Nickols, Maureen A ^b   Westlin, William F ^b   Ellis, Lee M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (3 BROMO 5 CHLORO 2 HYDROXYPHENYL) 3 [[N [[5 [(5 HYDROXY 1,4,5,6 TETRAHYDROPYRIMIDIN 2 YL)AMINO]PYRIDIN 3 YL]CARBONYL]GLYCYL]AMINO]PROPANOIC ACID; ANGIOGENESIS INHIBITOR; ANTIMITOTIC AGENT; ANTINEOPLASTIC AGENT; INTEGRIN; MATRIGEL; S 247; UNCLASSIFIED DRUG; VITRONECTIN; ORGANIC COMPOUND; S 247 COMPOUND; VITRONECTIN RECEPTOR;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER MODEL; CANCER SURVIVAL; CARCINOGENESIS; CELL ADHESION; CELL ASSAY; CELL CULTURE; CELL GROWTH; CELL MIGRATION; CELL STRAIN; COLON CARCINOMA; COLONY FORMATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG TARGETING; DYING; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INFUSION; LIVER BLOOD VESSEL; LIVER METASTASIS; MALE; METASTASIS INHIBITION; MOUSE; MOUSE STRAIN; NONHUMAN; OSMOTIC PUMP; PERICYTE; PRIORITY JOURNAL; SPLEEN; SPLEEN TUMOR; SUBCUTANEOUS TISSUE; SURVIVAL RATE; SURVIVAL TIME; ANIMAL; BAGG ALBINO MOUSE; CELL DIVISION; CELL MOTION; COLON TUMOR; CYTOLOGY; DISEASE MODEL; DRUG ANTAGONISM; LIVER TUMOR; METASTASIS; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIUM; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; APOPTOSIS; CELL ADHESION; CELL DIVISION; CELL MOVEMENT; COLONIC NEOPLASMS; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; HUMANS; INTEGRIN ALPHAVBETA3; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; NEOVASCULARIZATION, PATHOLOGIC; ORGANIC CHEMICALS; SIGNAL TRANSDUCTION;

EID: 0037728975     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Ivaska, J., and Heino, J. Adhesion receptors and cell invasion: mechanisms of integrin-guided degradation of extracellular matrix. Cell. Mol. Life Sci., 57: 16-24, 2000.
2. Hynes, R. O. Integrins: versatility, modulation, and signaling in cell adhesion. Cell, 69: 11-25, 1992.
3. Ruoslahti, E., and Pierschbacher, M. D. New perspectives in cell adhesion: RGD and integrins. Science (Wash. DC), 238: 491-497, 1987.
4. Friedlander, M., Theesfeld, C. L., Sugita, M., Fruttiger, M., Thomas, M. A., Chang, S., and Cheresh, D. A. Involvement of integrins α v β 3 and α v β 5 in ocular neovascular diseases. Proc. Natl. Acad. Sci. USA, 93: 9764-9769, 1996.
5. Brooks, P. C., Clark, R. A., and Cheresh, D. A. Requirement of vascular integrin α v β 3 for angiogenesis. Science (Wash. DC), 264: 569-571, 1994.
6. Gasparini, G., Brooks, P. C., Biganzoli, E., Vermeulen, P. B., Bonoldi, E., Dirix, L. Y., Ranieri, G., Miceli, R., and Cheresh, D. A. Vascular integrin α(v)β3: a new prognostic indicator in breast cancer. Clin. Cancer Res., 4: 2625-2634, 1998.
7. Brooks, P. C., Montgomery, A. M., Rosenfeld, M., Reisfeld, R. A., Hu, T., Klier, G., and Cheresh, D. A. Integrin α v β 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell, 79: 1157-1164, 1994.
8. Friedlander, M., Brooks, P. C., Shaffer, R. W., Kincaid, C. M., Vamer, J. A., and Cheresh, D. A. Definition of two angiogenic pathways by distinct α v integrins. Science (Wash. DC), 270: 1500-1502, 1995.
9. Kerr, J. S., Wexler, R. S., Mousa, S. A., Robinson, C. S., Wexler, E. J., Mohamed, S., Voss, M. E., Devenny, J. J., Czemiak, P. M., Gudzelak, A., Jr., and Slee, A. M. Novel small molecule α v integrin antagonists: comparative anti-cancer efficacy with known angiogenesis inhibitors. Anticancer Res., 19: 959-968, 1999.
10. Meyer, D., Nickols, G., Pegg, J., and Westlin, W. An oral αv β3 antagonist, S-247, induces tumor regression and inhibits hypercalcemia of malignancy in a syngeneic mouse colon model. Proc. Am. Assoc. Cancer Res., 42: 825, 2001.
11. Griggs, D., Shannon, K., Settle, S., Duffin, T., Nickols, M., Schroeter, S., Nickols, G., and Westlin, W. Anti-metastatic efficacy mediated by peptidomimetic α v β 3 integrin antagonists in orthotopic and experimental models. Proc. Am. Assoc. Cancer Res., 42: 263, 2001.
12. Lode, H. N., Moehler, T., Xiang, R., Jonczyk, A., Gillies, S. D., Cheresh, D. A., and Reisfeld, R. A. Synergy between an antiangiogenic integrin αv antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases. Proc. Natl. Acad. Sci. USA, 96: 1591-1596, 1999.
13. Bruns, C. J., Liu, W., Davis, D. W., Shaheen, R. M., McConkey, D. J., Wilson, M. R., Bucana, C. D., Hicklin, D. J., and Ellis, L. M. Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases. Cancer (Phila.), 89: 488-499, 2000.
14. Yatohgo, T., Izumi, M., Kashiwagi, H., and Hayashi, M. Novel purification of vitronectin from human plasma by heparin affinity chromatography. Cell Struct. Funct., 13: 281-292, 1988.
15. Pytela, R., Pierschbacher, M. D., Argraves, S., Suzuki, S., and Ruoslahti, E. Arginineglycine-aspartic acid adhesion receptors. Methods Enzymol., 144: 475-489, 1987.
16. Charo, I. F., Nannizzi, L., Phillips, D. R., Hsu, M. A., and Scarborough, R. M. Inhibition of fibrinogen binding to GP Ilb-IIIa by a GP IIIa peptide. J. Biol. Chem., 266: 1415-1421, 1991.
17. Rodbard, D., Munso, P. J., and de Lean, A. Improved curve fitting, parallelism testing, characterization of sensitivity and specificity, validation, and optimization for radioligand assays. Vienna: International Atomic Energy Agency, p. 469, 1977.
18. Geng, L., Ali, S. A., Marshall, J. F., Mackay, C. L., Hart, I. R., Delcommence, M., Streuli, C. H., and Rees, R. C. Fibronectin is chemotactic for CT 26 colon carcinoma cells: sub-lines selected for increased chemotaxis to fibronectin display decreased tumorigenicity and lung colonization. Clin. Exp. Metastasis, 16: 683-691, 1998.
19. Caltabiano, S., Hum, W. T., Attwell, G. J., Gralnick, D. N., Budman, L. J., Cannistraci, A. M., and Bex, F. J. The integrin specificity of human recombinant osteopontin. Biochem. Pharmacol., 58: 1567-1578, 1999.
20. Akagi, Y., Liu, W., Xie, K., Zebrowski, B., Shaheen, R. M., and Ellis, L. M. Regulation of vascular endothelial growth factor expression in human colon cancer by interleukin-1β. Br. J. Cancer, 80: 1506-1511, 1999.
21. Shaheen, R. M., Davis, D. W., Liu, W., Zebrowski, B. K., Wilson, M. R., Bucana, C. D., McConkey, D, J., McMahon, G., and Ellis, L. M. Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis. Cancer Res., 59: 5412-5416, 1999.
22. Reinmuth, N., Fan, F., Liu, W., Parikh, A. A., Stoeltzing, O., Jung, Y. D., Bucana, C. D., Radinsky, R., Gallick, G. E., and Ellis, L. M. Impact of insulin-like growth factor receptor-I function on angiogenesis, growth, and metastasis of colon cancer. Lab. Investig., 82: 1377-1389, 2002.
23. Eberhard, A., Kahlert, S., Goede, V., Hemmerlein, B., Plate, K. H., and Augustin, H. G. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res, 60: 1388-1393, 2000.
24. Weidner, N. Intratumor microvessel density as a prognostic factor in cancer. Am. J. Pathol., 147: 9-19, 1995.
25. Reinmuth, N., Liu, W., Jung, Y. D., Ahmad, S. A., Shaheen, R. M., Fan, F., Bucana, C. D., McMahon, G., Gallick, G. E., and Ellis, L. M. Induction of VEGF in perivascular cells defines a potential paracrine mechanism for endothelial cell survival. FASEB J., 15: 1239-1241, 2001.
26. Radinsky, R., and Ellis, L. M. Molecular determinants in the biology of liver metastasis. Surg. Oncol. Clin. N. Am., 5: 215-229, 1996.
27. Terayama, N., Terada, T., and Nakanuma, Y. An immunohistochemical study of tumour vessels in metastatic liver cancers and the surrounding liver tissue. Histopathology, 29: 37-43, 1996.
28. Fidler, I. J., Kumar, R., Bielenberg, D. R., and Ellis, L. M. Molecular determinants of angiogenesis in cancer metastasis. Cancer J. Sci. Am., 4 (Suppl. 1): S58-S66, 1998.
29. Ellerby, H. M., Arap, W., Ellerby, L. M., Kain, R., Andrusiak, R., Rio, G. D., Krajewski, S., Lombardo, C. R., Rao, R., Ruoslahti, E., Bredesen, D. E., and Pasqualini, R. Anti-cancer activity of targeted pro-apoptotic peptides. Nat. Med., 5: 1032-1038, 1999.
30. Vamer, J. A., and Cheresh, D. A. Integrins and cancer. Curr. Opin. Cell Biol., 8: 724-730, 1996.
31. Pasqualini, R., Bodorova, J., Ye, S., and Hemler, M. E. A study of the structure, function and distribution of β 5 integrins using novel anti-β 5 monoclonal antibodies. J. Cell Sci., 105 (Pt. 1): 101-111, 1993.
32. Felding-Habermann, B., and Cheresh, D. A. Vitronectin and its receptors. Curr. Opin. Cell Biol., 5: 864-868, 1993.
33. Yun, Z., Menter, D. G., and Nicolson, G. L. Involvement of integrin αvβ3 in cell adhesion, motility, and liver metastasis of murine RAW117 large cell lymphoma. Cancer Res., 56: 3103-3111, 1996.
34. O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., and Folkman, J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell, 88: 277-285, 1997.
35. Warren, R. S., Yuan, H., Matli, M. R., Gillett, N. A., and Ferrara, N. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J. Clin. Investig., 95: 1789-1797, 1995.
36. Klement, G., Baruchel, S., Rak, J., Man, S., Clark, K., Hicklin, D. J., Bohlen, P., and Kerbel, R. S. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J. Clin. Investig., 105: R15-R24, 2000.
37. Lehmann, M., Rabenandrasana, C., Tamura, R., Lissitzky, J. C., Quaranta, V., Pichon, J., and Marvaldi, J. A monoclonal antibody inhibits adhesion to fibronectin and vitronectin of a colon carcinoma cell line and recognizes the integrins α v β 3, α v β 5, and αv β 6. Cancer Res., 54: 2102-2107, 1994.
38. Klemke, R. L., Yebra, M., Bayna, E. M., and Cheresh, D. A. Receptor tyrosine kinase signaling required for integrin α v β 5-directed cell motility but not adhesion on vitronectin. J. Cell Biol., 127: 859-866, 1994.
39. Brooks, P. C., Klemke, R. L., Schon, S., Lewis, J. M., Schwartz, M. A., and Cheresh, D. A. Insulin-like growth factor receptor cooperates with integrin α v β 5 to promote tumor cell dissemination in vivo. J. Clin. Investig., 99: 1390-1398, 1997.
40. Hirschi, K. K., Rohovsky, S. A., Beck, L. H., Smith, S. R., and D'Amore, P. A. Endothelial cells modulate the proliferation of mural cell precursors via platelet-derived growth factor-BB and heterotypic cell contact. Circ. Res., 84: 298-305, 1999.
41. Zheng, B., and Clemmons, D. R. Blocking ligand occupancy of the αVβ3 integrin inhibits insulin-like growth factor I signaling in vascular smooth muscle cells. Proc. Natl. Acad. Sci. USA, 95: 11217-11222, 1998.
42. Jones, J. I., Prevette, T., Gockerman, A., and Clemmons, D. R. Ligand occupancy of the α-V-β3 integrin is necessary for smooth muscle cells to migrate in response to insulin-like growth factor. Proc. Natl. Acad. Sci. USA, 93: 2482-2487, 1996.
43. Chen, C. S., Mrksich, M., Huang, S., Whitesides, G. M., and Ingber, D. E. Geometric control of cell life and death. Science (Wash. DC), 276: 1425-1428, 1997.
44. Cary, L. A., Chang, J. F., and Guan, J. L. Stimulation of cell migration by overexpression of focal adhesion kinase and its association with Src and Fyn. J. Cell Sci., 109 (Pt. 7): 1787-1794, 1996.
45. Ilic, D., Furuta, Y., Kanazawa, S., Takeda, N., Sobue, K., Nakatsuji, N., Nomura, S., Fujimoto, J., Okada, M., and Yamamoto, T. Reduced cell motility and enhanced focal adhesion contact formation in cells from FAK-deficient mice. Nature (Lond.), 377: 539-544, 1995.
46. Gilmore, A. P., Metcalfe, A. D., Romer, L. H., and Streuli, C. H. Integrin-mediated survival signals regulate the apoptotic function of Bax through its conformation and subcellular localization. J. Cell Biol., 149: 431-446, 2000.
47. Rosen, K., Rak, J., Leung, T., Dean, N. M., Kerbel, R. S., and Filmus, J. Activated Ras prevents down-regulation of Bcl-X(L) triggered by detachment from the extracellular matrix. A mechanism of Ras-induced resistance to anoikis in intestinal epithelial cells. J. Cell Biol., 149: 447-456, 2000.
48. Blystone, S. D., Graham, I. L., Lindberg, F. P., and Brown, E. J. Integrin α v β 3 differentially regulates adhesive and phagocytic functions of the fibronectin receptor α 5 β 1. J. Cell Biol., 127: 1129-1137, 1994.